{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:43:31Z","timestamp":1776059011954,"version":"3.50.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is a lack of clinical data on hematopoietic stem cell transplantation (HSCT) in Ataxia-Telangiectasia (A-T) patients due to the underlying chromosomal instability that leads to low tolerance to chemotherapy. To effectively manage cancer and immune risks, there is a need for improved HSCT protocols, novel therapies, and long-term monitoring. This report describes a 16-year-old boy with A-T and T-ALL who achieved long-term leukemia-free survival after HSCT using a tailored, drug-monitored conditioning regimen. His results were analyzed in the context of a systematic review of the literature on HSCT outcomes in A-T patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A thorough literature review was conducted using a comprehensive search of the PubMed, Scopus, and Google Scholar databases. The search was limited to studies published between September 1, 2000, and September 1, 2025. Eligible studies were required to involve human participants and to include at least one patient with a confirmed diagnosis of A-T, with transplantation interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis included 16 A-T patients, including our patient, who underwent HSCT. The median age at transplantation was 48 months (interquartile range [IQR]: 22\u2013142 months). Myeloablative conditioning (MAC) was administered to two patients, both of whom died. Reduced-intensity conditioning (RIC) was utilized for nine patients, with three deaths (33.3%). Reduced-toxicity conditioning (RTC) was administered in two patients, with one patient experiencing a fatal outcome. In total, eight patients (50%) experienced significant drug-related toxicities, eight (50%) had GvHD and only eight patients (50%) survived. Our patient underwent HSCT of a matched sibling donor after administration of adjusted treosulfan doses (cumulative AUC of 4671 mg\/Lxh), and achieved leukemia-free survival with complete hematological and normalized thymic function without graft-versus-host disease (GvHD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite the historically poor survival outcomes observed in transplanted A-T patients, new HSCT strategies, such as treosulfan therapeutic drug monitoring and personalized drug profiles to select potent but less toxic agents, warrant reevaluation to achieve durable remission in leukemia and lymphoma. These findings underscore the necessity to persist in the development of innovative HSCT approaches with the objective of expanding therapeutic options for both malignancies and combined immunodeficiency.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1754093","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:48:28Z","timestamp":1776055708000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Systematic review of hematopoietic stem cell transplantation in patients with ataxia telangiectasia: a case report and an individual patient-level analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Hayrunnisa","family":"Bekis Bozkurt","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Allergy and Immunology, Umraniye Research and Training Hospital","place":["\u0130stanbul, T\u00fcrkiye"]},{"name":"Department of Stem Cell Transplantation, Z\u00fcrich University, Children\u2019s Hospital","place":["Z\u00fcrich, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia Meda","family":"Spaccamela","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation, Z\u00fcrich University, Children\u2019s Hospital","place":["Z\u00fcrich, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moustapha","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Division of Biomolecular and Cellular Medicine, Karolinska Institutet","place":["Stockholm, Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Felber","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation, Z\u00fcrich University, Children\u2019s Hospital","place":["Z\u00fcrich, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Zeilhofer","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation, Z\u00fcrich University, Children\u2019s Hospital","place":["Z\u00fcrich, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida","family":"Zeckanovic","sequence":"additional","affiliation":[{"name":"Department of Oncology, Z\u00fcrich University, Children\u2019s Hospital","place":["Z\u00fcrich, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Bourquin","sequence":"additional","affiliation":[{"name":"Department of Oncology, Z\u00fcrich University, Children\u2019s Hospital","place":["Z\u00fcrich, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jacquier","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology and Oncology, Vaud University Hospital Center","place":["Lausanne, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Ceppi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology and Oncology, Vaud University Hospital Center","place":["Lausanne, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Candotti","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Immunology, Vaud University Hospital Center","place":["Lausanne, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tayfun","family":"G\u00fcng\u00f6r","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation, Z\u00fcrich University, Children\u2019s Hospital","place":["Z\u00fcrich, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-87893-1_6","article-title":"Ataxia-telangiectasia (Louis-bar syndrome)","volume-title":"Neurocutaneous disorders: A clinical, diagnostic and therapeutic approach: third edition.","author":"Panteliadis","year":"2022"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e0264177","DOI":"10.1371\/journal.pone.0264177","article-title":"The natural history of ataxia-telangiectasia (A-T): A systematic review","volume":"17","author":"Petley","year":"2022","journal-title":"PloS One"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji141","article-title":"Cancer risks and mortality in heterozygous ATM mutation carriers","volume":"97","author":"Thompson","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.3747\/co.25.3707","article-title":"Ataxia\u2013telangiectasia gene (ATM) mutation heterozygosity in breast cancer: A narrative review","volume":"25","author":"Jerzak","year":"2018","journal-title":"Curr Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.5101","article-title":"Incidence, presentation, and prognosis of Malignancies in ataxia-telangiectasia: A report from the French national registry of primary immune deficiencies","volume":"33","author":"Suarez","year":"2015","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2016.05.012","article-title":"Treatment of acute leukemia in children with ataxia telangiectasia (A-T)","volume":"59","author":"Schoenaker","year":"2016","journal-title":"Eur J Med Genet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2017.09.001","article-title":"A study of the pharmacokinetic properties and the in vivo kinetics of erythrocytes loaded with dexamethasone sodium phosphate in healthy volunteers","volume":"32","author":"Coker","year":"2018","journal-title":"Transfus Med Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.3390\/cancers12113207","article-title":"Bone marrow transplantation as therapy for ataxia-telangiectasia: A systematic review","volume":"12","author":"de Oliveira","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e83304","DOI":"10.7759\/cureus.83304","article-title":"The use of bone marrow transplantation (BMT) or hematopoietic stem cell transplantation (HSCT) in pediatric patients diagnosed with ataxia-telangiectasia: A systematic review","volume":"17","author":"Alqarni","year":"2025","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-738070","article-title":"Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia","volume":"129","author":"Frismantas","year":"2017","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1715","article-title":"Proposed therapeutic range of treosulfan in reduced toxicity pediatric allogeneic hematopoietic stem cell transplant conditioning: Results from a prospective trial","volume":"108","author":"Chiesa","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2022.05.008","article-title":"Immune reconstitution after allogenic stem cell transplantation: An observational study in pediatric patients","volume":"45","author":"Belinovski","year":"2023","journal-title":"Hematol Transfus Cell Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.11124\/JBISRIR-D-19-00099","article-title":"Methodological quality of case series studies: An introduction to the jbi critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01378-8","article-title":"EBMT\/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity","volume":"56","author":"Lankester","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2017.01.009","article-title":"Ataxia-telangiectasia: immunodeficiency and survival","volume":"178","author":"van Os","year":"2017","journal-title":"Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.10.023","article-title":"Prevalence and outcomes of cancer and treatment-associated toxicities for patients with ataxia telangiectasia","volume":"155","author":"Magnarelli","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4226","article-title":"Bone marrow transplantation restores immune system function and prevents lymphoma in Atm-deficient mice","volume":"104","author":"Bagley","year":"2004","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/dds448","article-title":"Bone marrow transplantation improves the outcome of Atm-deficient mice through the migration of Atm-competent cells","volume":"22","author":"Pietzner","year":"2013","journal-title":"Hum Mol Genet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02495","article-title":"Pre-emptive allogeneic hematopoietic stem cell transplantation in ataxia telangiectasia","volume":"9","author":"Bakhtiar","year":"2018","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.93","article-title":"Allogeneic-matched sibling stem cell transplantation in a 13-year-old boy with ataxia telangiectasia and EBV-positive non-Hodgkin lymphoma","volume":"51","author":"Beier","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9654-7","article-title":"Fatal outcome despite full lympho-hematopoietic reconstitution after allogeneic stem cell transplantation in atypical ataxia telangiectasia","volume":"32","author":"Ghosh","year":"2012","journal-title":"J ClinImmunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.02.036","article-title":"Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders","volume":"141","author":"Slack","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.01.053","article-title":"Antibody deficiency in patients with ataxia telangiectasia is caused by disturbed B- and T-cell homeostasis and reduced immune repertoire diversity","volume":"131","author":"Driessen","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.07.001","article-title":"Allogeneic stem cell transplantation after Fanconi anemia conditioning in children with ataxia-telangiectasia results in stable T cell engraftment and lack of infections despite mixed chimerism","volume":"24","author":"Ussowicz","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01450-6","article-title":"Prospective newborn screening for SCID in Germany: A first analysis by the Pediatric Immunology Working Group (API)","volume":"43","author":"Speckmann","year":"2023","journal-title":"J ClinImmunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02785","article-title":"Hematopoietic stem cell transplantation restores na\u00efve T-cell populations in Atm-deficient mice and in preemptively treated patients with ataxia-telangiectasia","volume":"10","author":"Duecker","year":"2019","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.886540","article-title":"Case report: Rubella virus-induced cutaneous granulomas in two pediatric patients with DNA double strand breakage repair disorders \u2013 outcome after hematopoietic stem cell transplantation","volume":"13","author":"Baumann","year":"2022","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13020","article-title":"Ataxia-telangiectasia: A review of clinical features and molecular pathology","volume":"30","author":"Amirifar","year":"2019","journal-title":"Pediatr Allergy Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13023-016-0543-7","article-title":"Ataxia telangiectasia: A review","volume":"11","author":"Rothblum-Oviatt","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01571-y","article-title":"Early diagnosis of ataxia telangiectasia through newborn screening for SCID: A case report highlighting the dilemma of pre-emptive HSCT","volume":"43","author":"Weitering","year":"2023","journal-title":"J ClinImmunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1754093\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:48:37Z","timestamp":1776055717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1754093\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2026.1754093"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1754093","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"article-number":"1754093"}}